The United Kingdom and the United States have forged a key commercial pact that will keep zero import taxes on UK medicine products going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the public health system. This move ensures that tariffs on these vital products will remain at nothing for a timeframe of 36 months.
This development comes after recent statements to significantly raise import taxes on patented pharmaceutical imports, with potential rates mentioned reaching double the cost.
"This deal with the UK strengthens the worldwide climate for new treatments and establishes much-needed equity to U.S.–U.K. medicine commerce," an announcement noted.
Trade Importance
Pharmaceuticals represent one of the Britain's most significant export categories to the America, which is easily the biggest buyer for major UK drugmakers.
Trade data show that in the 12 months leading up to last September, the UK sold drugs valued at billions to the US. This value made up a significant portion of all goods exports in that span.
"This deal protects employment, increases funding and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The pact includes several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments were more than 20%.
Industry Background
This agreement comes amid a long-running tension between the drug companies and the UK government over medicine costs and regulatory access.
This friction were heightened by arguments that US patients were charged significantly more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been paused or scrapped, while major expansions have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
